Actively Recruiting

Phase 2
Age: 12Years +
All Genders
NCT06388564

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Led by Incyte Corporation · Updated on 2026-03-23

120

Participants Needed

70

Research Sites

268 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of axatilimab to the combination treatment effect in participants with cGVHD.

CONDITIONS

Official Title

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • 12 years of age or older at the time of informed consent
  • New-onset moderate or severe chronic graft-versus-host disease requiring systemic therapy
  • History of one allogeneic stem cell transplant of any donor type, conditioning regimen, or stem cell source
  • Adequate blood counts independent of platelet transfusion and growth factors for at least 7 days before study entry: ANC ≥ 0.75 x 10^9/L and platelets ≥ 20 x 10^9/L
  • Willingness to avoid pregnancy or fathering children
Not Eligible

You will not qualify if you...

  • More than one prior allogeneic stem cell transplant; prior autologous transplant allowed
  • Presence of overlap chronic graft-versus-host disease with acute features
  • Previous systemic treatment for chronic graft-versus-host disease, including corticosteroids and extracorporeal photopheresis
  • Systemic corticosteroids within 2 weeks before study day 1
  • Started systemic treatment with calcineurin inhibitors or mTOR inhibitors within 2 weeks before study day 1
  • Prior JAK inhibitor treatment within 8 weeks before randomization, except those treated for acute GVHD who responded and did not discontinue due to toxicity
  • Evidence of relapse or treatment for relapse of the primary hematologic disease after transplant
  • History of acute or chronic pancreatitis
  • Thromboembolic events within 6 months before study entry
  • Active symptomatic myositis
  • Severe kidney impairment (creatinine clearance <30 mL/min) or on dialysis; creatinine clearance 30-59 mL/min with fluconazole treatment also excluded
  • Impaired liver function (total bilirubin >1.5 times upper limit normal and/or ALT and AST >3 times upper limit normal without liver cGVHD)
  • Active significant heart disease such as uncontrolled arrhythmias, uncontrolled hypertension, severe heart failure, or recent heart attack or unstable angina within 6 months
  • Pregnant or breastfeeding

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 70 locations

1

Mayo Clinic Hospital

Phoenix, Arizona, United States, 85054

Actively Recruiting

2

City of Hope Medical Center

Duarte, California, United States, 91010

Actively Recruiting

3

University of California-Los Angeles Medl Cntr-Oncology Center Bowyer Clinic

Los Angeles, California, United States, 90095

Actively Recruiting

4

Stanford Cancer Center

Stanford, California, United States, 94305

Actively Recruiting

5

University of Colorado Cancer Center

Aurora, Colorado, United States, 80045

Actively Recruiting

6

Colorado Blood Cancer Institute

Denver, Colorado, United States, 80218

Actively Recruiting

7

Smilow Cancer Center-Yale

New Haven, Connecticut, United States, 06510

Actively Recruiting

8

Mayo Clinic Jacksonville

Jacksonville, Florida, United States, 32224

Actively Recruiting

9

Northwestern University

Chicago, Illinois, United States, 60611

Actively Recruiting

10

The University of Chicago Medicine

Chicago, Illinois, United States, 60637

Actively Recruiting

11

University of Maryland-Greenebaum Cancer Center

Baltimore, Maryland, United States, 21201

Actively Recruiting

12

Massachusetts General Hospital

Boston, Massachusetts, United States, 02144

Withdrawn

13

Washington University

St Louis, Missouri, United States, 63110

Actively Recruiting

14

Fred and Pamela Buffett Cancer Center

Omaha, Nebraska, United States, 68198

Actively Recruiting

15

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10021

Actively Recruiting

16

Weill Cornell Medicine

New York, New York, United States, 10021

Actively Recruiting

17

Mount Sinai Hospital

New York, New York, United States, 10029

Actively Recruiting

18

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Actively Recruiting

19

The Ohio State University

Columbus, Ohio, United States, 43210

Actively Recruiting

20

University of Pennsylvania Abramson Cancer Center

Philadelphia, Pennsylvania, United States, 19104

Actively Recruiting

21

Hillman Cancer Center

Pittsburgh, Pennsylvania, United States, 15232

Actively Recruiting

22

Vanderbilt University Medical Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

23

Md Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

24

Fred Hutchinson Cancer Center

Seattle, Washington, United States, 98109

Actively Recruiting

25

University of Washington

Seattle, Washington, United States, 98195

Actively Recruiting

26

Froedtert & the Medical College of Wisconsin

Milwaukee, Wisconsin, United States, 53226

Actively Recruiting

27

Az Sint-Jan Brugge - Oostende Av - Campus Sint-Jan

Bruges, Belgium, 08000

Actively Recruiting

28

Universitair Ziekenhuis Antwerpen (Uza)

Edegem, Belgium, 02650

Actively Recruiting

29

Jessa Ziekenhuis

Hasselt, Belgium, 03500

Actively Recruiting

30

Universitair Ziekenhuis (Uz) Leuven

Leuven, Belgium, 03000

Actively Recruiting

31

Universitaire Ziekenhuis Leuven - Gasthuisberg

Leuven, Belgium, 03000

Actively Recruiting

32

Centre Hospitalier Universitaire (Chu) de Liege

Liège, Belgium, 04000

Actively Recruiting

33

AZ DELTA

Roeselare, Belgium, 08800

Actively Recruiting

34

Arthur J E Child Comprehensive Cancer Centre

Calgary, Alberta, Canada, T3N 4N1

Actively Recruiting

35

Princess Margaret Cancer Centre - University Health Network

Toronto, Ontario, Canada, M5G 2M9

Actively Recruiting

36

Chu Sainte-Justine

Montreal, Quebec, Canada, H3T 1C5

Actively Recruiting

37

Vancouver General Hospital

Vancouver, Canada, V5Z1M9

Actively Recruiting

38

Klinikum Der Johann Wolfgang Goethe University

Frankfurt am Main, Germany, 60590

Actively Recruiting

39

Universitatklinikum Freiburg

Freiburg im Breisgau, Germany, 79106

Actively Recruiting

40

Universitatsklinikum Hamburg Eppendorf

Hamburg, Germany, 20251

Actively Recruiting

41

Universitaetsklinikum Jena

Jena, Germany, 07747

Actively Recruiting

42

University Hospital Mannheim

Mannheim, Germany, 68167

Actively Recruiting

43

Universitaetsklinikum Regensburg

Regensburg, Germany, 93053

Actively Recruiting

44

Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii

Bergamo, Italy, 24127

Actively Recruiting

45

Aou Policlinico S. Orsola-Malpighi

Bologna, Italy, 40138

Actively Recruiting

46

Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico Di Milano Uo Dermatologia

Milan, Italy, 20122

Actively Recruiting

47

Ospedale Pediatrico Bambino Gesu Irccs

Rome, Italy, 00165

Actively Recruiting

48

Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore

Rome, Italy, 00168

Actively Recruiting

49

Irccs Istituto Clinico Humanitas

Rozzano, Italy, 20089

Actively Recruiting

50

A.O.U. Citta Della Salute E Della Scienza Di Torino

Torino, Italy, 10126

Actively Recruiting

51

Hospital General Universitario Vall D Hebron

Barcelona, Spain, 08035

Withdrawn

52

Hospital Clinic Barcelona Main

Barcelona, Spain, 08036

Actively Recruiting

53

Hospital Universitario Virgen de La Arrixaca

El Palmar, Spain, 30120

Actively Recruiting

54

Hospital Universitario Virgen de Las Nieves

Granada, Spain, 18014

Actively Recruiting

55

Ico Institut Catala D Oncologia

Granvia de L'hospitalet 199-203, Spain, 08908

Actively Recruiting

56

Hospital General Universitario Gregorio Maranon

Madrid, Spain, 28007

Actively Recruiting

57

Hospital Universitario Ramon Y Cajal

Madrid, Spain, 28034

Actively Recruiting

58

Hospital Universitario 12 de Octubre

Madrid, Spain, 28041

Actively Recruiting

59

Hospital Regional Universitario de Malaga

Málaga, Spain, 29011

Actively Recruiting

60

Hospital Clinico Universitario de Salamanca

Salamanca, Spain, 37007

Actively Recruiting

61

Hospital Universitario Marques de Valdecilla

Santander, Spain, 39008

Actively Recruiting

62

Hospital Universitario Virgen Del Rocio

Seville, Spain, 41013

Actively Recruiting

63

Hospital Clinico Universitario de Valencia

Valencia, Spain, 46010

Actively Recruiting

64

Hospital Universitari I Politecnic La Fe

Valencia, Spain, 46026

Actively Recruiting

65

Queen Elizabeth Hospital

Birmingham, United Kingdom, B15 2TH

Actively Recruiting

66

Cambridge University Hospitals Nhs Foundation Trust

Cambridge, United Kingdom, CB2 0QQ

Actively Recruiting

67

University Hospital of Wales

Cardiff, United Kingdom, CF14 4XW

Actively Recruiting

68

Queen Elizabeth University Hospital

Glasgow, United Kingdom, G51 4TF

Actively Recruiting

69

St James University Hospital

Leeds, United Kingdom, LS9 7TF

Actively Recruiting

70

Clatterbridge Cancer Center

Liverpool, United Kingdom, L7 8YA

Actively Recruiting

Loading map...

Research Team

I

Incyte Corporation Call Center (US)

CONTACT

I

Incyte Corporation Call Center (ex-US)

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease | DecenTrialz